Literature DB >> 1397775

Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat.

B Bravenboer1, A C Kappelle, F P Hamers, T van Buren, D W Erkelens, W H Gispen.   

Abstract

It has been shown that parameters of oxidative stress are increased in experimental diabetic neuropathy. The glutathione redox system is one of the intracellular scavenger systems for neutralizing free oxygen radicals. In this investigation we studied the effect of glutathione-treatment on the development of diabetic neuropathy in streptozotocin-induced diabetic rats by measuring sensory and motor nerve conduction velocities. The total study period was 10 weeks. Four groups of rats were studied: Group 1 consisted of non-diabetic, age-matched control rats; Group 2, of diabetic rats treated with placebo from week 0 to 10; Group 3, of diabetic rats treated with 200 mg glutathione/kg body weight i.v. two times per week from weeks 0 to 10; and Group 4, of diabetic rats treated with placebo from weeks 0 to 4 and as Group 3 from weeks 4 to 10. The sensory and motor nerve conduction velocity of rats treated prophylactically with glutathione (Group 3) were significantly different from those of rats treated with placebo (Group 2) or with glutathione administered at a later time point (Group 4). Complete restoration of sensory and motor nerve conduction velocity was not reached. There was a significant improvement in motor nerve conduction velocity from weeks 4 to 6 (p less than 0.005), but not in sensory nerve conduction velocity in the delayed treatment group (Group 4). In conclusion, treatment with glutathione, a free radical scavenger, is partially effective in the prevention of diabetic neuropathy in streptozotocin-induced diabetic rats, but is of limited value when the neuropathy is already present.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397775     DOI: 10.1007/bf00399926

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat.

Authors:  P De Koning; W H Gispen
Journal:  Peptides       Date:  1987 May-Jun       Impact factor: 3.750

2.  Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve.

Authors:  F J Romero; J Segura-Aguilar; E Monsalve; C Hermenegildo; E Nies; F J Puertas; J Romá
Journal:  Neurotoxicol Teratol       Date:  1990 Nov-Dec       Impact factor: 3.763

3.  Oxygen free radical effects in sciatic nerve in experimental diabetes.

Authors:  P A Low; K K Nickander
Journal:  Diabetes       Date:  1991-07       Impact factor: 9.461

4.  Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats.

Authors:  C E Van der Zee; R G Van der Hoop; W H Gispen
Journal:  Diabetes       Date:  1989-02       Impact factor: 9.461

5.  Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.

Authors:  D Finegold; S A Lattimer; S Nolle; M Bernstein; D A Greene
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

6.  Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozocin-induced diabetes.

Authors:  D Loven; H Schedl; H Wilson; T T Daabees; L D Stegink; M Diekus; L Oberley
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

7.  Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy.

Authors:  P A Low; J D Schmelzer; K K Ward; J K Yao
Journal:  Am J Physiol       Date:  1986-01

8.  Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Diabetes       Date:  1983-07       Impact factor: 9.461

9.  Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy.

Authors:  P A Low; R R Tuck; P J Dyck; J D Schmelzer; J K Yao
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.

Authors:  D R Tomlinson; R J Moriarty; J H Mayer
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

View more
  29 in total

1.  Taurine reduces nitrosative stress and nitric oxide synthase expression in high glucose-exposed human Schwann cells.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

2.  Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model.

Authors:  Brian Fink; Lawrence Coppey; Eric Davidson; Hanna Shevalye; Alexander Obrosov; Pratik Rajesh Chheda; Robert Kerns; William Sivitz; Mark Yorek
Journal:  Free Radic Res       Date:  2020-04-24

3.  Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine.

Authors:  M Sagara; J Satoh; R Wada; S Yagihashi; K Takahashi; M Fukuzawa; G Muto; Y Muto; T Toyota
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 4.  Diabetes and the Small Intestine.

Authors:  Jonathan Gotfried; Stephen Priest; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost.

Authors:  M A Cotter; K C Dines; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

Review 6.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

7.  Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

Review 8.  Role of oxidative stress and Ca²⁺ signaling on molecular pathways of neuropathic pain in diabetes: focus on TRP channels.

Authors:  Mustafa Nazıroğlu; Döndü Merve Dikici; Seyda Dursun
Journal:  Neurochem Res       Date:  2012-07-31       Impact factor: 3.996

9.  ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.

Authors:  B Bravenboer; A C Kappelle; T van Buren; D W Erkelens; W H Gispen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

10.  Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids.

Authors:  C Karasu; M Dewhurst; E J Stevens; D R Tomlinson
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.